Nrx Pharmaceuticals Stock Current Valuation
| NRXP Stock | USD 1.31 0.02 1.55% |
Valuation analysis of NRX Pharmaceuticals helps investors to measure NRX Pharmaceuticals' intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. As of 11/29/2024, Enterprise Value Over EBITDA is likely to grow to -1.25. In addition to that, Enterprise Value Multiple is likely to grow to -1.25. Fundamental drivers impacting NRX Pharmaceuticals' valuation include:
Price Book 2.9042 | Enterprise Value 20.6 M | Enterprise Value Ebitda (0.15) |
Undervalued
Today
Please note that NRX Pharmaceuticals' price fluctuation is very risky at this time. Calculation of the real value of NRX Pharmaceuticals is based on 3 months time horizon. Increasing NRX Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
NRX Pharmaceuticals' intrinsic value may or may not be the same as its current market price of 1.31, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.31 | Real 1.75 | Target 3.08 | Hype 1.34 |
The intrinsic value of NRX Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence NRX Pharmaceuticals' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of NRX Pharmaceuticals helps investors to forecast how NRX stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of NRX Pharmaceuticals more accurately as focusing exclusively on NRX Pharmaceuticals' fundamentals will not take into account other important factors: NRX Pharmaceuticals Company Current Valuation Analysis
NRX Pharmaceuticals' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current NRX Pharmaceuticals Current Valuation | 20.62 M |
Most of NRX Pharmaceuticals' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, NRX Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
NRX Current Valuation Driver Correlations
Understanding the fundamental principles of building solid financial models for NRX Pharmaceuticals is extremely important. It helps to project a fair market value of NRX Stock properly, considering its historical fundamentals such as Current Valuation. Since NRX Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of NRX Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of NRX Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
NRX Current Valuation Historical Pattern
Today, most investors in NRX Pharmaceuticals Stock are looking for potential investment opportunities by analyzing not only static indicators but also various NRX Pharmaceuticals' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current valuation growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of NRX Pharmaceuticals current valuation as a starting point in their analysis.
NRX Pharmaceuticals Current Valuation |
| Timeline |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, NRX Pharmaceuticals has a Current Valuation of 20.62 M. This is 99.86% lower than that of the Biotechnology sector and 99.56% lower than that of the Health Care industry. The current valuation for all United States stocks is 99.88% higher than that of the company.
NRX Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses NRX Pharmaceuticals' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of NRX Pharmaceuticals could also be used in its relative valuation, which is a method of valuing NRX Pharmaceuticals by comparing valuation metrics of similar companies.NRX Pharmaceuticals is currently under evaluation in current valuation category among its peers.
NRX Fundamentals
| Return On Equity | -6.83 | ||||
| Return On Asset | -1.16 | ||||
| Current Valuation | 20.62 M | ||||
| Shares Outstanding | 12.09 M | ||||
| Shares Owned By Insiders | 23.56 % | ||||
| Shares Owned By Institutions | 6.00 % | ||||
| Number Of Shares Shorted | 667 K | ||||
| Price To Book | 2.90 X | ||||
| EBITDA | (30.02 M) | ||||
| Net Income | (30.15 M) | ||||
| Cash And Equivalents | 24.55 M | ||||
| Cash Per Share | 0.36 X | ||||
| Total Debt | 9.16 M | ||||
| Debt To Equity | 0.02 % | ||||
| Current Ratio | 4.58 X | ||||
| Book Value Per Share | (1.42) X | ||||
| Cash Flow From Operations | (21.66 M) | ||||
| Short Ratio | 4.80 X | ||||
| Earnings Per Share | (2.11) X | ||||
| Target Price | 31.33 | ||||
| Beta | 1.27 | ||||
| Market Capitalization | 15.6 M | ||||
| Total Asset | 7.32 M | ||||
| Retained Earnings | (253.15 M) | ||||
| Working Capital | (12.16 M) | ||||
| Net Asset | 7.32 M |
About NRX Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze NRX Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of NRX Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of NRX Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with NRX Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if NRX Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in NRX Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving together with NRX Stock
Moving against NRX Stock
| 0.88 | EWTX | Edgewise Therapeutics | PairCorr |
| 0.81 | GILD | Gilead Sciences | PairCorr |
| 0.8 | ESPR | Esperion Therapeutics Buyout Trend | PairCorr |
| 0.8 | BMY | Bristol Myers Squibb Sell-off Trend | PairCorr |
| 0.73 | GANX | Gain Therapeutics | PairCorr |
The ability to find closely correlated positions to NRX Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace NRX Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back NRX Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling NRX Pharmaceuticals to buy it.
The correlation of NRX Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as NRX Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if NRX Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for NRX Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for NRX Stock Analysis
When running NRX Pharmaceuticals' price analysis, check to measure NRX Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NRX Pharmaceuticals is operating at the current time. Most of NRX Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of NRX Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NRX Pharmaceuticals' price. Additionally, you may evaluate how the addition of NRX Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.